Romulus TX is a precision immunology company developing therapeutic antibodies that selectively eliminate pathogenic immune cell subsets to reset the immune system in autoimmune diseases. By targeting the cellular drivers of disease rather than cytokines, their platform aims to provide durable disease control without broad immunosuppression, leveraging insights from human genetics and immune biology.
Funding
Funding not disclosed
Founders
Product
Problem
Current autoimmune therapies often rely on broad cytokine blockade, which can suppress the immune system indiscriminately and lead to side effects while failing to address the underlying cellular drivers of disease.
Solution
RomulusTX develops precision antibody therapeutics that selectively eliminate pathogenic immune cell subsets responsible for driving autoimmune pathology. By targeting these cellular drivers rather than downstream inflammatory mediators, the approach aims to achieve a durable functional reset of the immune system without widespread immunosuppression. The platform integrates insights from human genetics and immune biology to identify disease‑relevant cell populations and designs antibodies that deplete them with high specificity. This strategy seeks to provide long‑lasting disease control and reduce the need for continuous immunosuppressive treatment.
Target Audience
Primary customers are pharmaceutical companies and biotech firms developing treatments for autoimmune diseases, as well as academic research groups seeking precision immunology tools.
Features
- Antibody formats engineered for selective binding to surface markers unique to pathogenic immune subsets
- Human genetics‑guided target selection to ensure relevance across diverse autoimmune indications
- Mechanisms of action focused on targeted cellular depletion while sparing protective immune cells
- Translational pipeline that moves from genetic discovery to preclinical validation and clinical candidate generation
- Platform designed for modular adaptation to multiple autoimmune diseases based on shared cellular drivers